Raj Chakraborty
@rajshekharucms
Hematologist/Oncologist/Clinical Researcher @ColumbiaCancer #Myeloma #Amyloidosis Asst. Prof @ColumbiaMed Host @BloodCancerTalk COI: http://tinyurl.com/chty956p
This was the first article from which I learnt how to interpret crossover in RCTs. A must read for all trainees!
Academic read of the day! Crossover in oncology? A concise, open-access, 2-page paper clearly framing when it is is desirable, and when its problematic, by @AlysonHaslam & @VPrasadMDMPH in @Annals_Oncology Seminal 2018 paper and still as relevant! ➡️bit.ly/3TZCOUc
In another multicenter (@columbiacancer and @BrighamWomens) study of BCMA BsAb in AL Amyloidosis (including stage IIIb), brisk and deep hematologic responses translating into organ responses, despite short follow-up! Now we need: Prospective data Long term follow up to test…
#Myeloma Paper of the Day: Case series of elranatamab for relapsed &/or refractory advanced stage AL #amyloidosis finds 100% ORR & 67% CR rate; median time to heme response of 9 days (6-24), translating into cardiac & renal responses at 3-6 months: pubmed.ncbi.nlm.nih.gov/40712156/. #mmsm
#Myeloma Paper of the Day: Study of myeloma patient preferences on clinical decision making concludes that many choose against treatments that improve PFS if they do not positively affect OS and lead to clinical, financial, and/or time toxicities: pubmed.ncbi.nlm.nih.gov/40705989/. #mmsm
🎧 NEW EPISODE ALERT! 🎧 Dive deep into follicular lymphoma management with Dr. Gilles Salles @MSKCancerCenter! From watchful waiting to bispecifics & CAR-T - we cover it all. 🔬 Key trials: RELEVANCE, GALLIUM, InMIND & more Listen now! 🎙️ @Eddie_Cliff share.transistor.fm/s/4fba389f
Contextualizing results of randomized trials in smoldering myeloma academic.oup.com/oncolo/advance… via @ManniMD1 & @aarongoodman33 & @rajshekharucms @Eddie_Cliff
Shout out to @ManniMD1 @rajshekharucms, @HealthTree, @JayHydren, @amandeepgodara7, @BrianMcClune @Eddie_Cliff, and all the other coauthors on this paper investigating patient preferences in shared clinical decision making! drive.google.com/file/d/1ts6f8e…
🚨 How to contextualize the rapidly evolving data in High-Risk Smoldering Myeloma? New article in @OncJournal where @ManniMD1 & Dr. Aaron Goodman and I summarize our take on the data: ✅ What events are we actually preventing (mostly SLiM or renal failure/fractures? ) ✅ Does…
Yes. Writing is not a second thing that happens after thinking. The act of writing is an act of thinking. Writing *is* thinking. Students, academics, and anyone else who outsources their writing to LLMs will find their screens full of words and their minds emptied of thought.
Check our recent work @BloodAdvances @UAMSMyeloma led by @asis_shr #mmsm The Efficacy of Teclistamab in Multiple Myeloma Patients with Secondary Plasma Cell Leukemia ➡️n=16 sPCL, ORR: 31% (lower than typical MM ORR ~63%) ➡️Prior BCMA exposure = no response - all 4 patients with…
As @FDAOncology’s ODAC weighed in today on the future of belantamab-based triplets, revisit this timely episode of @BloodCancerTalk with @HangQuach1, where we break down DREAMM-7 & DREAMM-8 and explore belantamab’s evolving role in myeloma treatment. 🎧 @Eddie_Cliff…
Our new episode-"Belantamab makes a comeback" with @HangQuach1 just dropped! We critically appraised DREAMM-7 and DREAMM-8 trials, and there are lots of clinical pearls on how to mitigate ocular toxicity! tinyurl.com/sen8cjnc Here is a clip on eye tox with belantamab:
The Phase III CARES trial of #anselamimab in #ALAmyloidosis did not meet its primary endpoint, but showed clinically meaningful benefit in a predefined high-risk subgroup. More details to follow at upcoming meetings. @BU_Amyloidosis astrazeneca.com/media-centre/p…
71% annual decrease in ASCT for AL amyloidosis since 2019 with Dara-CyBorD introduction; mainly used in patients with suboptimal response, rel/ref AL, LPL clone, or higher PC burden #bmtsm #mmsm #amyloid @MayoMyeloma @MorieGertz ashpublications.org/bloodadvances/…
A trend rapidly getting worse. Way too many in academia, government and Pharma make a living backing inertia, deflecting institutional risk, stalling projects over paranoid scenarios, without ever facing the urgency coming from patients.
Early initiation of daratumumab combinations improves renal function and provides an approach that avoids plasmapheresis. ow.ly/4l8850Wn7Qu #clinicaltrialsandobservations #lymphoidneoplasia
Most committees address solutions looking for problems
Thanks @rajshekharucms for highlighting the methodological aspects of this trial, totally agree. We need to be careful when we interpret these data.
👍🏻 article by @ManniMD1 @TomerMeirson et al on how the marginal PFS benefit in BOSTON trial (XVd vs Vd) could well be an artifact of imbalanced censoring (let alone the delinquent control arm and inappropriate crossover)! #mmsm academic.oup.com/oncolo/article…
A thoughtful and nuanced discussion on the results of MIDAS trial #mmsm #bmtsm @rajshekharucms @Eddie_Cliff @MeeraMohanMD podcasts.apple.com/us/podcast/blo…
👍🏻 article by @ManniMD1 @TomerMeirson et al on how the marginal PFS benefit in BOSTON trial (XVd vs Vd) could well be an artifact of imbalanced censoring (let alone the delinquent control arm and inappropriate crossover)! #mmsm academic.oup.com/oncolo/article…
